Acute and chronic studies of an oligomeric derivative of 1,10-bis-(2-hydroxyethylthio)-decane

A. Roda, P. Simoni, B. Grigolo, G. Scapini, V. Tumiatti, N. Ghedini

Research output: Contribution to journalArticle

Abstract

A new oligomeric derivative of thiadenol (TAD), in which the active principle is polyesterified with a bicarboxylic acid, has been studied as new retard-release prodrug (TAD-235). The compound has been acutely administered to rats and humans in order to assess, after oral administration, the dose-response serum levels of released TAD by means of a specific and sensitive enzyme immunoassay. The serum levels have been compared with those obtained by administration of TAD at equimolar dose. The results suggest an optimal bioavailability of the drug without high serum levels which, on the contrary, are constant over at least a 20-hour period. Finally, the prodrug TAD-235 was administered chronically to humans at a single daily dose of 500 mg/day, corresponding to 400 mg/day of active principle, which is five to six times lower than the dose of TAD currently used in the treatment of hyperlipidemic patients. A significant reduction of cholesterol and triglyceride levels has been observed after one month of treatment, suggesting the potential usefulness of TAD-235 as new hypolipidemic drug.

Original languageEnglish
Pages (from-to)839-845
Number of pages7
JournalCurrent Therapeutic Research
Volume42
Issue number5
Publication statusPublished - 1987

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Acute and chronic studies of an oligomeric derivative of 1,10-bis-(2-hydroxyethylthio)-decane'. Together they form a unique fingerprint.

  • Cite this

    Roda, A., Simoni, P., Grigolo, B., Scapini, G., Tumiatti, V., & Ghedini, N. (1987). Acute and chronic studies of an oligomeric derivative of 1,10-bis-(2-hydroxyethylthio)-decane. Current Therapeutic Research, 42(5), 839-845.